Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
Overview
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
Associated Conditions
- Chronic Myelogenous Leukemia (CML)
- Essential Thrombocythemia (ET)
- Head and Neck Primary Squamous Cell Carcinoma
- Hypereosinophilic Syndrome (HES)
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
- Meningiomas
- Polycythemia Vera (PV)
- Sickle Cell Crisis
- Vaso-occlusive Crisis
Clinical Trials
FDA Approved Products
DROXIA
Manufacturer:H2-Pharma LLC
Route:ORAL
Strength:200 mg in 1 1
Approved: 2022/10/05
NDC:61269-402
DROXIA
Manufacturer:E.R. Squibb & Sons, L.L.C.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2022/11/21
NDC:0003-6337
Hydroxyurea
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:500 mg in 1 1
Approved: 2024/02/14
NDC:70518-0916
Hydroxyurea
Manufacturer:Cardinal Health 107, LLC
Route:ORAL
Strength:500 mg in 1 1
Approved: 2022/04/18
NDC:55154-3554
HYDROXYUREA
Manufacturer:Teva Pharmaceuticals USA, Inc.
Route:ORAL
Strength:500 mg in 1 1
Approved: 2022/03/07
NDC:0555-0882
Singapore Approved Products
HYDRINE CAPSULES 500 mg
Manufacturer:KOREA UNITED PHARM. INC.
Form:CAPSULE
Strength:500 mg
Online:Yes
Approved: 1999/08/25
Approval:SIN11083P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath